IOVA Stock Overview
A commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Iovance Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.24 |
| 52 Week High | US$18.33 |
| 52 Week Low | US$3.21 |
| Beta | 0.65 |
| 1 Month Change | -9.46% |
| 3 Month Change | 11.91% |
| 1 Year Change | 39.13% |
| 3 Year Change | -43.27% |
| 5 Year Change | -40.64% |
| Change since IPO | 96.61% |
Recent News & Updates
Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Recent updates
Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
May 10Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Apr 09Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Mar 25Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Feb 20Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Jan 19Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
Sep 27Iovance submits rolling license application to FDA for skin cancer treatment lifileucel
Aug 25Calculating The Fair Value Of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Aug 25
Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Aug 04Iovance: TIL Cell Therapy Set To Prove Itself
Jul 11Iovance: Onward To Approval
Apr 20Iovance Biotherapeutics: An Unproven Biopharmaceutical Company With Significant Upside
Mar 25Iovance Biotherapeutics: Uncertainty And Opportunity
Dec 05Iovanve Biotherapeutics (IOVA) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 16Iovance Bio reports 33-month follow up data for lifileucel in advanced melanoma at ASCO21
Jun 07Iovance: Down And Rebound
May 30Shareholder Returns
| IOVA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 3.2% | 1.7% |
| 1Y | 39.1% | 6.2% | 26.3% |
Return vs Industry: IOVA exceeded the US Biotechs industry which returned 6% over the past year.
Return vs Market: IOVA exceeded the US Market which returned 26.3% over the past year.
Price Volatility
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IOVA's share price has been volatile over the past 3 months.
Volatility Over Time: IOVA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 557 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.
Iovance Biotherapeutics, Inc. Fundamentals Summary
| IOVA fundamental statistics | |
|---|---|
| Market cap | US$2.87b |
| Earnings (TTM) | -US$449.64m |
| Revenue (TTM) | US$1.90m |
1,505x
P/S Ratio-6.4x
P/E RatioIs IOVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IOVA income statement (TTM) | |
|---|---|
| Revenue | US$1.90m |
| Cost of Revenue | US$18.02m |
| Gross Profit | -US$16.11m |
| Other Expenses | US$433.53m |
| Earnings | -US$449.64m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | -846.22% |
| Net Profit Margin | -23,615.70% |
| Debt/Equity Ratio | 0.1% |
How did IOVA perform over the long term?
See historical performance and comparison